CD117

• CD117, or c-KIT, is a receptor tyrosine kinase essential for cell growth and survival.
• It is involved in the development and function of several cell types, including hematopoietic stem cells and mast cells.
• CD117 serves as a valuable diagnostic and prognostic marker in specific cancers, such as gastrointestinal stromal tumors (GIST) and acute myeloid leukemia (AML).
• Targeted therapies that inhibit CD117 activity have revolutionized the treatment of certain CD117-positive malignancies.

What is CD117 (c-KIT)?

CD117, also known as c-KIT, is a transmembrane receptor tyrosine kinase (RTK) protein. It belongs to the type III receptor tyrosine kinase family, which includes receptors for platelet-derived growth factor (PDGF), colony-stimulating factor 1 (CSF-1), and Fms-like tyrosine kinase 3 (FLT3). This CD117 protein overview reveals it is encoded by the KIT gene and is crucial for regulating cell proliferation, differentiation, migration, and apoptosis. The protein’s structure includes an extracellular domain that binds its ligand, stem cell factor (SCF), a transmembrane domain, and an intracellular tyrosine kinase domain responsible for initiating downstream signaling pathways upon ligand binding.

Under normal physiological conditions, CD117 is expressed on the surface of various cell types. These include hematopoietic stem cells, mast cells, germ cells, melanocytes, and the interstitial cells of Cajal (ICC) in the gastrointestinal tract. Its proper functioning is essential for processes such as hematopoiesis (blood cell formation), melanogenesis (pigment production), fertility, and gastrointestinal motility. Dysregulation of CD117 activity, often due to activating mutations in the KIT gene, can lead to uncontrolled cell growth and is implicated in the pathogenesis of several human cancers.

CD117 Function and Its Role as a Marker

The primary CD117 function and role involves mediating cellular responses to stem cell factor (SCF). When SCF binds to the extracellular domain of CD117, it causes the receptor to dimerize and undergo autophosphorylation of its intracellular tyrosine kinase domain. This phosphorylation event activates a cascade of intracellular signaling pathways, including the RAS/MAPK, PI3K/AKT, and JAK/STAT pathways, which collectively promote cell survival, proliferation, and differentiation. For example, in mast cells, CD117 signaling is vital for their development, survival, and activation, contributing to allergic and inflammatory responses.

As a diagnostic and prognostic marker, the CD117 marker meaning is particularly significant in oncology. Its expression is routinely assessed in several types of cancer to aid in diagnosis, predict prognosis, and guide treatment decisions.

Here are some key conditions where CD117 acts as an important marker:

• Gastrointestinal Stromal Tumors (GIST): Approximately 80-85% of GISTs are characterized by activating mutations in the KIT gene, leading to constitutive activation of the CD117 receptor. CD117 positivity is a hallmark of GIST, making it a crucial diagnostic marker and a primary target for tyrosine kinase inhibitors like imatinib.
• Acute Myeloid Leukemia (AML): CD117 is expressed on leukemic blasts in a significant subset of AML patients, particularly those with core-binding factor leukemias (e.g., t(8;21) and inv(16)). Its presence can influence prognosis and may indicate potential responsiveness to CD117-targeting agents.
• Systemic Mastocytosis: This rare disorder is characterized by the abnormal proliferation and accumulation of mast cells, often driven by a specific activating mutation (D816V) in the KIT gene, leading to hyperactive CD117 signaling. CD117 expression is a defining feature of mast cells and is central to the diagnosis of mastocytosis.
• Melanoma: While less common than in GIST, CD117 mutations and overexpression can occur in a subset of melanomas, particularly those arising from mucosal or acral sites, offering another potential therapeutic target.

According to the World Health Organization (WHO), CD117 immunohistochemistry is a standard diagnostic tool for GIST, with its presence confirming the diagnosis in most cases. The identification of CD117 expression and specific KIT gene mutations has transformed the management of these diseases, allowing for the development of highly effective targeted therapies that specifically inhibit the aberrant activity of the CD117 receptor.